慢性髓性白血病（Chronic Myeloid Leukemia, CML）是一种以骨髓增生异常为特征的血液恶性肿瘤，其发病机制复杂，治疗策略多样。尽管靶向药物治疗如酪氨酸激酶抑制剂（TKIs）在慢性期（Chronic Phase, CP）CML治疗中取得了显著进展，但一旦疾病进展至急变期（Blast Crisis, BC），患者预后往往不佳，亟需新的治疗策略。然...
参考文献 Maymona G. Abdelmagid, Aref Al-Kali,et al. Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial...
Michele Baccarani,et al.questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid.Leukemia . 2022 Mar 25. doi: 10.1038/s41375-022-01522-3
[9] Timothy Hughes, et al. RAPID AND DEEP RESPONSES WITH ASCIMINIB IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) AFTER ≥2 PRIOR TYROSINE KINASE INHIBITORS (TKIS) IN THE PHASE 3 ASCEMBL...
Nilotinib superior to imatinib in older patients with CML in chronic phaseTraci Dantoni
Efficacy and safe-ty of a specific inhibitor of the BCR-ABL tyrosine kinasein chronic myeloid leukemia[J]. N Engl J Med，2001，344（14）：1 031.[5 ] Kantarjian HM，Larson RA，Guilhot F，et al. Efficacy ofimatinib dose escalation in patients with chronic myeloidleukemia in chronic phase[...
Incidence of Hyperglycemia by 3 Years in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib (NIL) or Imatinib (IM) in ENESTnd doi:10.1182/blood.V120.21.1686.16861686Background:ENESTnd established the superior efficacy of frontline NIL vs ...
Chronic myeloid leukemia (CML) has served as a paradigm for the development of effective initial and next-generation targeted therapies. The availability of five effective and generally well-tolerated BCR::ABL1 tyrosine kinase inhibitors for the treatment of newly diagnosed chronic phase CML offers ...
An abstract is unavailable.doi:10.1097/01.COT.0000312323.54585.fdFuerstMarkOncology Times
III. Predictive parameters in the chronic phase. Cancer Genet Cytogenet 14: 227–234Sadamori N, Sandberg AA. Chromosome changes and splenectomy in Ph1-positive chronic myeloid leukemia. I. Predictive parameters in the blastic phase. Cancer 1984; 54: 2456-2459....